Author

Juan Lucas Bayo Calero

Observed names: J.L. Bayo Calero, Juan Bayo Calero, Juan L Bayo Calero, Juan L. Bayo Calero, L. Bayo Calero, Juan

Institution: Hospital Juan Ramón Jiménez

Observed institution: Hospital Juan Ramón Jiménez

OpenAlex ID: A5111773680

Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01

2024 · Aditya Bardia, Komal Jhaveri, et al. · Journal of Clinical Oncology · 256

The Long-HER Study: Clinical and Molecular Analysis of Patients with HER2+ Advanced Breast Cancer Who Become Long-Term Survivors with Trastuzumab-Based Therapy

2014 · Angelo Gámez-Pozo, Ramón M. Pérez Carrión, et al. · PLoS ONE · 24

[Physicians' awareness and assessment of shared decision making in oncology practice.]

2019 · Nuria Padilla Garrido, Francisco Aguado Correa, et al. · PubMed Central · 9

Multidisciplinary onco–critical care management: Clinical impact.

2026 · Irene Valencia, Beatriz Buendía Cruz, et al. · Journal of Clinical Oncology

Abstract P4-04-24: Cytokeratin 19 mRNA copy number by one-step nucleic acid amplification (OSNA) in the sentinel lymph node biopsy (SLNB) as prognostic factor in Luminal early Breast Cancer (LeBC)

2025 · Maria Yeray Rodriguez Garces, Stephanie Saide Cobelas Cartagena, et al. · Clinical Cancer Research

Can vitamin D deficiency be considered a risk factor be considered a risk factor in luminal breast cancer?

2024 · Laura Fernández Madrigal, María Yeray Rodríguez Garcés, et al. · Journal of Clinical Oncology

1728P Implementation of a comprehensive oncology unit: Needs detected in cancer survivors during follow-up

2023 · F.J. Jimenez-Ruiz, M.Y. Rodriguez Garces, et al. · Annals of Oncology

Efficacy and safety of neoadjuvant double anti-Her2 blockade combined with anthracycline-free chemotherapy in locally advanced breast cancer.

2023 · Maria Yeray Rodriguez Garcés, Victoria García Samblás, et al. · Journal of Clinical Oncology

146P Updated survival analysis in NEOPERSUR trial: Neoadjuvant pertuzumab in a real-world population in the south of Spain

2023 · A. Falcon Gonzalez, J. Cruz Jurado, et al. · ESMO Open

2023 · Domínguez Senin, Loreto, Morales Pancorbo, David, et al. · Figshare

Cross-sectional observational study to describe the clinicopathological and biological characteristics and the management of patients with HER2+ metastatic breast cancer who experienced complete or partial remission or disease stabilization during at least 3 years: LongHer study.

2012 · Pilar Zamora, Juan Angel Fresno-Vara, et al. · Journal of Clinical Oncology

Works count: 11

Citation count: 289

H-index: 3

I10-index: 2